Abstract:Background: Clinical and immunological studies in humans show that the live attenuated Bacillus Calmette-Guérin (BCG) vaccine has beneficial non-specific effects, increasing resistance against diseases other than tuberculosis. The underlying mechanisms are currently being explored. The pig exhibits considerable physiological similarity to humans in anatomy and physiology, suggesting that similar responses to BCG could be expected. Studies of the non-specific effects of BCG in pigs are scarce. We investigated the feasibility of using pigs as a large animal model to investigate the non-specific immunological effects of BCG. Methods: In a series of experiments, we randomized newborn or young piglets from conventional farms to receiving BCG or placebo and investigated the persistence of live BCG bacteria in various tissues, the immunogenicity of BCG in ex vivo blood and in vitro stimulation assays, and the acute phase protein and clinical responses to heterologous infectious challenge with influenza A virus or Actinobacillus pleuropneumoniae . Results: The BCG vaccine was generally well tolerated. In contrast to humans, no skin reaction in the form of abscesses, ulcers, or scars was observed. Live BCG was recovered from draining lymph nodes in 2/13 animals 20 weeks after vaccination. Specific in vitro responses of IFN-γ to antigen-specific re-stimulation with mycobacterial antigen were increased but not TNF-responses to TLR2 or TLR4 agonists. A few genes were differentially expressed in blood after vaccination, including the antiviral genes RIG-I and CSF1 , although the effect disappeared after correction for multiple testing. Clinical symptoms after heterologous bacterial or viral respiratory infections did not differ, nor did virus copies in nasopharyngeal samples after the challenge. However, the acute phase protein response was significantly reduced in BCG-vaccinated animals after influenza challenge but not after A. pleuropneumoniae challenge. Discussion: BCG was safe in pigs, inducing specific immunological responses, but our model did not corroborate the innate immunological responsiveness to BCG seen in humans. The dose of BCG or the bacterial and viral challenges may have been sub-optimal. Even so, the acute phase protein response to influenza infection was significantly reduced in BCG-vaccinated animals.

Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen

A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes

A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice

Novel Recombinant Bcg Coexpressing Ag85b, Esat-6 And Rv2608 Elicits Significantly Enhanced Cellular Immune And Antibody Responses In C57bl/6 Mice

Immune Responses and Protective Efficacy Induced by 85B Antigen and Early Secreted Antigenic Target-6 Kda Antigen Fusion Protein Secreted by Recombinant Bacille Calmette-Guérin

Increased B and T Cell Responses in M. bovis Bacille Calmette-Guérin Vaccinated Pigs Co-Immunized with Plasmid DNA Encoding a Prototype Tuberculosis Antigen

Recombinant Mycobacterium Bovis Bacillus Calmette-Gue'Rin Elicits Human Immunodeficiency Virus Type 1 Envelope-Specific T Lymphocytes At Mucosal Sites

Evaluation of a Recombinant BCG Expressing Antigen Ag85B and PPE Protein Rv3425 from DNA Segment RD11 of Mycobacterium Tuberculosis in C57BL/6 Mice

Development of Mixed Th1/Th2 Type Immune Response and Protection Against Mycobacterium tuberculosis After Rectal or Subcutaneous Immunization of Newborn and Adult Mice with Mycobacterium bovis BCG

Intravenous Bacillus Calmette-Guérin (BCG) Induces a More Potent Airway and Lung Immune Response than Intradermal BCG in Simian Immunodeficiency Virus-infected Macaques

Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response.

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Rv3620c Elicits Specific Th1 Immune Responses in C57bl/6 Mice

Immunogenicity of Bacillus Calmette-Guérin in pigs: potential as a translational model of non-specific effects of BCG

Recombinant Bacille Calmette-Guérin coexpressing Ag85B-IFN-γ enhances the cell-mediated immunity in C57BL/6 mice.

Mycobacterium Bovis BCG Surface Antigens Expressed under the Granuloma-Like Conditions As Potential Inducers of the Protective Immunity.

Oral inoculation of recombinant BCG expressing Der p2 in the form of lipoprotein induces antigen-specific TH1 predominant immune response in mice

PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4+ T cell transcriptomal molecular signatures

Intravenous BCG induces a more potent airway and lung immune response than intradermal BCG in SIV-infected macaques

Recombinant BCG to Enhance Its Immunomodulatory Activities

Evaluation Of A New Recombinant Bcg Which Contains Mycobacterial Antigen Ag85b-Mpt64(190-198)-Mtb8.4 In C57/Bl6 Mice

Immune responses induced by BCG prime and single dose of recombinant adenovirus Ad5-CEAB boosted strategy in mice